Actively Recruiting
Center Without Walls for Imaging Proteinopathies With PET (CW2IP2): Phase I Pilot Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-M503
Led by University of Pennsylvania · Updated on 2026-04-24
70
Participants Needed
3
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the distribution, metabolism, excretion, and brain uptake of a new radiotracer called 11C-M503. This tracer is designed to measure abnormal alpha-synuclein deposits in the brains of people with Parkinson's disease (PD). The study will compare tracer uptake in individuals with PD, multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and healthy volunteers. This multi-center research project is funded by an NIH U19 grant and involves collaboration among several universities, with the University of Pennsylvania acting as the central review board.
CONDITIONS
Brief Title
Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 40 to 85 years
- Male or female participants
- Willing and able to provide written informed consent
- Clinical diagnosis of Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, or healthy control as determined by consensus committee
- Participants with PD, MSA, or PSP are asked but not required to agree to brain donation
You will not qualify if you...
- Females who are pregnant or breastfeeding
- Parkinsonism forms other than PD, PSP, or MSA
- Major psychiatric disorders such as schizophrenia or bipolar disorder (major depressive disorder allowed)
- History of significant or ongoing alcohol or substance abuse
- Inability to tolerate imaging, arterial line or IV placement, or blood draws
- Contraindications to MRI, such as incompatible implanted devices
- Any medical condition considered by a physician to compromise participant safety or study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 weeks
Participants undergo PET scans with 11C-M503 and may also have a brain MRI, Amyloid PET scan, and neurological assessments to evaluate brain uptake and other diagnostic measures.
1 to 2 visits depending on imaging and assessments
Duration - Up to 4 weeks
Participants are monitored for safety and any adverse events following the imaging procedures.
Approximately 1 follow-up visit
Trial Site Locations
Total: 3 locations
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06510
Actively Recruiting
2
Washington University in St. Louis
St Louis, Missouri, United States, 63110
Actively Recruiting
3
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
E
Erin Schubert
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here